Bright Minds Biosciences Inc.
DRUGNASDAQHealthcare● Active
$65.28
$-3.72(-5.39%)
Market Cap$506671699
P/E Ratio—
52W High$123.75
52W Low$23.175
Bright Minds Biosciences Inc. (DRUG) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DRUG · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 20, 2026EPS Actual
-$0.80
Est. -$1.17 · +31.6%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 20, 2026
After Market Close
▲ Beat EPS🔥 6-Quarter EPS Beat Streak
DRUG reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.20
Rev. $3.50B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.20
Rev. Est.$3.50B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$1.28 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 20, 2026 | -$1.17 | -$0.80 | +31.6% | — | — | — |
| ▲ Q1 FY2026 | Feb 12, 2026 | -$0.98 | -$0.70 | +28.6% | — | — | — |
| ▲ Q4 FY2025 | Dec 23, 2025 | -$0.56 | -$0.41 | +27.1% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.59 | -$0.53 | +10.2% | — | — | — |
| ▲ Q1 FY2025 | Feb 13, 2025 | -$0.23 | $0.01 | +104.3% | — | — | — |
| ▲ Q4 FY2024 | Dec 30, 2024 | -$0.44 | -$0.12 | +72.9% | — | — | — |
| — Q3 FY2024 | Aug 14, 2024 | — | $0.04 | — | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$1.28
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 20, 2026Beat
EPS Actual
-$0.80
EPS Est.
-$1.17
EPS Surpr.
+31.6%
Revenue
—
Q1 FY2026
Feb 12, 2026Beat
EPS Actual
-$0.70
EPS Est.
-$0.98
EPS Surpr.
+28.6%
Revenue
—
Q4 FY2025
Dec 23, 2025Beat
EPS Actual
-$0.41
EPS Est.
-$0.56
EPS Surpr.
+27.1%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.53
EPS Est.
-$0.59
EPS Surpr.
+10.2%
Revenue
—
Q1 FY2025
Feb 13, 2025Beat
EPS Actual
$0.01
EPS Est.
-$0.23
EPS Surpr.
+104.3%
Revenue
—
Q4 FY2024
Dec 30, 2024Beat
EPS Actual
-$0.12
EPS Est.
-$0.44
EPS Surpr.
+72.9%
Revenue
—
Q3 FY2024
Aug 14, 2024
EPS Actual
$0.04
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $-3.88 | $-3.88 | $-3.88 | 1 |
| Q2 FY2027 | $-3.40 | $-3.40 | $-3.40 | 1 |
| Q1 FY2027 | $-3.23 | $-3.23 | $-3.23 | 2 |
| Q4 FY2026 | $-2.82 | $-2.82 | $-2.82 | 2 |
| Q3 FY2026 | $-3.11 | $-2.45 | $-1.79 | 4 |
| Q2 FY2026 | $-2.31 | $-1.78 | $-1.24 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 20, 2026 | +31.6% | $74.54 | $82.78 | +11.05% |
| ▲ Q1 FY2026 | Feb 12, 2026 | +28.6% | $77.92 | $80.57 | +3.40% |
| ▲ Q4 FY2025 | Dec 23, 2025 | +27.1% | $83.01 | $84.27 | +1.52% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +10.2% | $40.55 | $42.54 | +4.91% |
| ▲ Q1 FY2025 | Feb 13, 2025 | +104.3% | $45.18 | $45.72 | +1.20% |
| ▲ Q4 FY2024 | Dec 30, 2024 | +72.9% | $39.88 | $36.86 | -7.57% |
| — Q3 FY2024 | Aug 14, 2024 | — | $1.05 | $1.01 | -3.81% |
| — Q2 FY2024 | May 15, 2024 | — | $1.07 | $1.09 | +1.87% |
Q2 FY2026+11.05%
Report Date
May 20, 2026
EPS Beat/Miss
+31.6%
Price Before
$74.54
Price After
$82.78
Q1 FY2026+3.40%
Report Date
Feb 12, 2026
EPS Beat/Miss
+28.6%
Price Before
$77.92
Price After
$80.57
Q4 FY2025+1.52%
Report Date
Dec 23, 2025
EPS Beat/Miss
+27.1%
Price Before
$83.01
Price After
$84.27
Q3 FY2025+4.91%
Report Date
Aug 14, 2025
EPS Beat/Miss
+10.2%
Price Before
$40.55
Price After
$42.54
Q1 FY2025+1.20%
Report Date
Feb 13, 2025
EPS Beat/Miss
+104.3%
Price Before
$45.18
Price After
$45.72
Q4 FY2024-7.57%
Report Date
Dec 30, 2024
EPS Beat/Miss
+72.9%
Price Before
$39.88
Price After
$36.86
Q3 FY2024-3.81%
Report Date
Aug 14, 2024
EPS Beat/Miss
—
Price Before
$1.05
Price After
$1.01
Q2 FY2024+1.87%
Report Date
May 15, 2024
EPS Beat/Miss
—
Price Before
$1.07
Price After
$1.09
Avg Beat Reaction+2.42%
Beat Rate6 / 8 quarters
Largest Move+11.05% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DRUG ends December
Bright Minds Biosciences Inc. (DRUG) most recently reported earnings on May 20, 2026 for Q2 FY2026, posting EPS of $-0.80 — beating the analyst consensus of $-1.17 by +31.6%. DRUG has beaten EPS estimates for 6 consecutive quarters. The next DRUG earnings date is expected around September 1, 2026.
Each quarter, investors track DRUG earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DRUG revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DRUG's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DRUG earnings · 5 questionsBright Minds Biosciences Inc.'s next earnings report is expected around September 1, 2026. DRUG typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DRUG historically reports after market close (AMC).
DRUG earnings datewhen is DRUG earningsDRUG next earnings datewhen does DRUG report earningsDRUG earnings calendar
▸ Source: FMP · Bright Minds Biosciences Inc. SEC filings · US GAAP · Bright Minds Biosciences Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026